A randomised, double-blind, placebo-controlled, multicentre clinical trial of AZD1656 in diabetic patients hospitalised with COVID-19: The ARCADIA Trial - implications for therapeutic immune modulation

BACKGROUND: A potential immunotherapeutic role for AZD1656 (a glucokinase activator) in the treatment of COVID-19 was hypothesized. The ARCADIA trial investigated the safety and efficacy of AZD1656 in diabetic patients admitted to hospital with COVID-19. METHODS: The ARCADIA trial was a Phase II ran...

Descripción completa

Detalles Bibliográficos
Autores principales: Chorlton, Jamie, Hollowood, Zoe, Dyer, Carlene, Lockhart, Donna, Boekman, Pascal, McCafferty, Kieran, Coffey, Pete, Marelli-Berg, Federica, Martin, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9386394/
https://www.ncbi.nlm.nih.gov/pubmed/35996565
http://dx.doi.org/10.1016/j.eclinm.2022.101604

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9386394/
https://www.ncbi.nlm.nih.gov/pubmed/35996565
http://dx.doi.org/10.1016/j.eclinm.2022.101604

Ejemplares similares